Skip to main content
TipRanks
Go Ultimate75% OFF

Allergy Therapeutics (AGY) AI Stock Analysis

17 Followers
GB:AGY

Allergy Therapeutics

(LSE:AGY)

Select Model
Rating:38Underperform
Price Target:GBX 1.00â–¼(-18.37% Downside)
Action:reiterated
Date:11/20/26

Primarily driven by poor financial performance with negative equity, high debt, and cash burn, reinforced by weak technical momentum below key averages and unattractive valuation from negative P/E.

Positive Factors
Specialty allergy focusA focused position in allergy immunotherapy and diagnostics gives the company a defined therapeutic niche rather than a broad, unfocused portfolio. Its products are intended to address underlying causes of allergies, supporting a differentiated clinical proposition over symptom-only management.
Negative Factors
Severe margin compressionThe steep decline in gross margin shows that revenue is producing materially less gross profit than it did previously. Unless reversed, this erosion limits the funds available for research, commercial investment and overhead absorption, making durable profitability harder to achieve.

Allergy Therapeutics (AGY) vs. iShares MSCI United Kingdom ETF (EWC)

-100%-75%-50%-25%0%25%50%GB:AGY-86.39%EWC+11.69%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 77.57M
Dividend Yield
―
Average Volume (3M)
994.95K
Price to Earnings (P/E)
-1.4
Beta (1Y)
0.96
Revenue Growth
8.77%
EPS Growth
-7.14%
Country
UK
Employees
584
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Allergy Therapeutics Business Overview & Revenue Model

Company Description

Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside dia...

Allergy Therapeutics Financial Statement Overview

Summary

Severe strain from negative equity of -10.4M, rising debt to 67M, negative operating cash flow of -32.1M, margin drop from 73% to 41%, and ongoing net losses despite 4.5% revenue rebound.

Income Statement

28Negative

Balance Sheet

12Very Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue59.87M59.87M55.04M55.20M59.59M72.77M
Gross Profit24.78M24.78M25.13M29.74M32.69M48.95M
EBITDA-36.34M-36.34M-29.43M-30.74M-36.24M-8.69M
Net Income-51.51M-51.51M-40.13M-40.22M-43.07M-13.78M
Balance Sheet
Total Assets87.19M87.19M67.54M64.83M66.77M72.95M
Cash, Cash Equivalents and Short-Term Investments24.20M24.20M12.79M12.91M14.85M20.52M
Total Debt67.00M67.00M60.09M30.99M35.99M10.53M
Total Liabilities97.56M97.56M95.74M61.12M64.70M35.18M
Stockholders Equity-10.37M-10.37M-28.19M3.71M2.07M37.77M
Cash Flow
Free Cash Flow-37.06M-37.06M-31.98M-35.54M-35.59M-17.17M
Operating Cash Flow-32.13M-32.13M-28.72M-32.14M-30.92M-14.11M
Investing Cash Flow-4.65M-4.65M-3.15M-1.20M-4.67M-3.06M
Financing Cash Flow48.09M48.09M32.04M31.43M29.91M-2.64M

Allergy Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price1.23

Price Trends

50DMA3.78Negative
100DMA4.77Negative
200DMA7.35Negative

Market Momentum

MACD-0.81Positive
RSI9.64Positive
STOCH41.14Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGY, the sentiment is Negative. The current price of 1.23 is below the 20-day moving average (MA) of 2.32, below the 50-day MA of 3.78, and below the 200-day MA of 7.35, indicating a bearish trend. The MACD of -0.81 indicates Positive momentum. The RSI at 9.64 is Positive, neither overbought nor oversold. The STOCH value of 41.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AGY.

Allergy Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:AGY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:HIKGB:HIK74OutperformGBP 3.49B12.3415.05%3.76%2.48%3.36%
GB:VLGGB:VLG65NeutralGBP 81.42M15.717.82%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:STXGB:STX43NeutralGBP 32.76M-4.0864.57%―36.19%60.75%
GB:AGYGB:AGY38UnderperformGBP 77.57M-1.391684.19%―8.77%-7.14%

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:AGYGB:HIKGB:STXGB:VLGGB:BXPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:AGY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:AGYAllergy Therapeutics1.23-8.08-86.83%
GB:HIKHikma Pharmaceuticals1687.00149.719.74%
GB:STXShield Therapeutics3.05-4.65-60.39%
GB:VLGVenture Life68.5010.0017.09%
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS57.5020.2954.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026